First AMPA antagonist from Eisai's grows treatment options for refractory epilepsy
This article was originally published in Scrip
Executive Summary
Perampanel has become the first AMPA receptor antagonist to gain approval for the adjunctive treatment of partial-onset seizures. Despite underwhelming clinical trial data and relatively late market entry, perampanel's novel class, convenient dosing regimen, and preferable side-effect profile will support its uptake in the refractory patient population.